Your session is about to expire
← Back to Search
Therapeutic Drug Monitoring for Rheumatoid Arthritis (TDM-RA Trial)
TDM-RA Trial Summary
This trial is testing whether a proactive, individualized approach to therapy optimization, based on serum drug levels and the presence or absence of anti-drug antibodies, results in a higher rate of achieving and/or maintaining therapeutic goal compared to standard of care in patients with RA.
TDM-RA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTDM-RA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TDM-RA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had infections that stopped my treatment before.I have been on steroid therapy for over 2 months.I have been diagnosed with rheumatoid arthritis.I am taking or starting adalimumab, 40 mg under the skin every two weeks.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are eligible to partake in this research trial?
"Yes, the information on clinicaltrials.gov states that this trial is actively looking for participants to join. It was first advertised on October 26th 2022 and last updated one day later; 50 patients are required from 1 location."
Is this medical experiment open to new participants?
"As indicated by clinicaltrials.gov, this trial is actively enrolling patients with the most recent update taking place on October 27th 2022. The study was originally posted online just a day earlier on October 26th 2022."
Share this study with friends
Copy Link
Messenger